Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Part A & B: Overall Survival (OS)

OS

Time frame: Randomization to disease progression or death from any cause (Estimated as approximately 5 years).

Part A & B: Change from baseline in health-related quality of life (HRQoL), measured by European Organization for Research & Treatment of CancerQualityofLifeQuestionnaire-Core 30 (EORTC QLQ-C30)

Change from baseline in HRQoL, measured by the EORTC QLQ-C30

Time frame: Randomization through end of treatment (Estimated as approximately 3 years).

Part B: Objective Response Rate (ORR) per RECIST 1.1 by BICR

ORR per RECIST 1.1 by BICR

Time frame: Randomization to disease progression or death from any cause (Estimated as approximately 3 years).

Part B: Duration of Response (DOR) per RECIST 1.1 by BICR

DOR per RECIST 1.1 by BICR

Time frame: Randomization to disease progression or death from any cause (Estimated as approximately 3 years).

Part B: Disease Control Rate (DCR) per RECIST 1.1 by BICR

DCR per RECIST 1.1 by BICR

Time frame: Randomization to disease progression or death from any cause (Estimated as approximately 3 years).

Part B: Time to Response (TTR) per RECIST 1.1 by BICR

TTR per RECIST 1.1 by BICR

Time frame: Randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 3 years).

Part B: Progression-Free Survival 2 (PFS2) by investigator assessment

PFS2 by investigator assessment

Time frame: Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 3 years).]

Part B: Changes in Non-Small Cell Lung Cancer (NSCLC)-related symptoms, measured by the NSCLC-Symptom Assessment Questionnaire (SAQ)

Changes in NSCLC-related symptoms, measured by the NSCLC-SAQ

Time frame: Randomization through end of treatment (Estimated as approximately 3 years).

Part B: Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ

Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ

Time frame: Randomization through end of treatment (Estimated as approximately 3 years).

Part B: Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ

Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ

Time frame: Randomization through end of treatment (Estimated as approximately 3 years).